Injection Drug Use and Hepatitis C: From Transmission to Treatment

2003 ◽  
Vol 33 (6) ◽  
pp. 377-382 ◽  
Author(s):  
Diana L Sylvestre
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug

scholarly journals Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals

2015 ◽  
Vol 69 (3) ◽  
pp. 348-354 ◽  
Author(s):  
Margaret T. May ◽  
Amy C. Justice ◽  
Kate Birnie ◽  
Suzanne M. Ingle ◽  
Colette Smit ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug

Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history

AIDS ◽  
2014 ◽  
Vol 28 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Angela Cescon ◽  
Keith Chan ◽  
Janet M. Raboud ◽  
Ann N. Burchell ◽  
Jamie I. Forrest ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Clinical Outcomes ◽  
Injection Drug Use ◽  
Injection Drug

The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression

2010 ◽  
Vol 53 (2) ◽  
pp. 245-251 ◽  
Author(s):  
Ava John-Baptiste ◽  
Murray Krahn ◽  
Jenny Heathcote ◽  
Audery Laporte ◽  
George Tomlinson
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Natural History ◽  
Injection Drug Use ◽  
Meta Analysis ◽  
Injection Drug ◽  
Hepatitis C Infection ◽  
History Of ◽  
Meta Regression

scholarly journals The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment

2021 ◽  
Vol 47 (12) ◽  
pp. 505-514
Author(s):  
Lillian Lourenço ◽  
Marian Kelly ◽  
Jill Tarasuk ◽  
Kyla Stairs ◽  
Maggie Bryson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Harm Reduction ◽  
Injection Drug Use ◽  
Injection Drug ◽  
Health Concern ◽  
Prescription Opioid ◽  
Direct Acting Antiviral ◽  
Life Years ◽  
Hcv Transmission

Hepatitis C continues to be a significant public health concern in Canada, with the hepatitis C virus (HCV) responsible for more life-years lost than all other infectious diseases in Canada. An increase in reported hepatitis C infections was observed between 2014 and 2018. Here, we present changing epidemiological trends and discuss risk factors for hepatitis C acquisition in Canada that may have contributed to this increase in reported hepatitis C infections, focusing on injection drug use. We describe a decrease in the use of borrowed needles or syringes coupled with an increase in using other used injection drug use equipment. Also, an increased prevalence of injection drug use and use of prescription opioid and methamphetamine injection by people who inject drugs (PWID) may be increasing the risk of HCV acquisition. At the same time, while harm reduction coverage appears to have increased in Canada in recent years, gaps in access and coverage remain. We also consider how direct-acting antiviral (DAA) eligibility expansion may have affected hepatitis C rates from 2014 to 2018. Finally, we present new surveillance trends observed in 2019 and discuss how the coronavirus disease 2019 (COVID-19) pandemic may affect hepatitis C case counts from 2020 onwards. Continual efforts to i) enhance hepatitis C surveillance and ii) strengthen the reach, effectiveness, and adoption of hepatitis C prevention and treatment services across Canada are vital to reducing HCV transmission among PWID and achieving Canada’s HCV elimination targets by 2030.

scholarly journals Predictors of Active Injection Drug Use in a Cohort of Patients Infected With Hepatitis C Virus

2013 ◽  
Vol 103 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Carrie Reed ◽  
Caleb Bliss ◽  
Sherri O. Stuver ◽  
Timothy Heeren ◽  
Sheila Tumilty ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug

scholarly journals Hepatitis C in hemodialysis: the contribution of injection drug use

2010 ◽  
Vol 14 (4) ◽  
pp. 422-426
Author(s):  
Bruno Galperim ◽  
Angelo A. Mattos ◽  
Airton T. Stein ◽  
Nuttiane C. Schneider ◽  
André Buriol ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug

scholarly journals Distribution of Hepatitis C Virus Genotypes in Canada: Results from the LCDC Sentinel Health Unit Surveillance System

1999 ◽  
Vol 10 (1) ◽  
pp. 53-56 ◽  
Author(s):  
RK Chaudhary ◽  
M Tepper ◽  
S Eisaadany ◽  
Paul R Gully
Keyword(s):  
Risk Factor ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Injection Drug Use ◽  
Injection Drug Users ◽  
Drug Users ◽  
Injection Drug ◽  
Major Risk Factor ◽  
Hcv Rna

In a sentinel hepatitis surveillance study conducted by sentinel health units, 1469 patients were enrolled, and 959 (65.3%) were positive for antibody to hepatitis C virus (HCV). Samples from 387 patients (40.4%) were tested for HCV RNA, and 289 (74.7%) were positive for RNA. The major risk factor for HCV infection was injection drug use, reported in 71% of cases. The genotyping of HCV isolates showed that subtype 1a (48%) was predominant in Canada. The other subtypes detected were 1b (19%), 2a (6%), 2b (3%), 3a (22%) and 4a (1%). In Winnipeg, Manitoba, subtype 3a (47%) was more prevalent than subtype 1a (37%), and, in Guelph, Ontario, both subtypes 1a and 3a had equal (40%) distribution. The prevalence of subtype 3a was significantly higher in injection drug users (27%) than in nonusers (10%) (P<0.005). In Canada, injection drug use is the major risk factor for HCV infections, and subtype 1a is more prevalent.

Sign in / Sign up

Export Citation Format

Share Document